|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice显示文摘 | Einar M. Sigurdsson Youssef Z. Wadghiri Lisa Mosconi Jeffrey A. Blind Elin Knudsen Ayodeji Asuni Henrieta Scholtzova Wai H. Tsui Yongsheng Li Martin Sadowski Daniel H. Turnbull Mony J. de Leon Thomas Wisniewski | 2007 | Neurobiology of Aging2007，，6： | 1 |
| 2 | The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer显示文摘 | Clarence K. W. Wong Richard N. Fedorak Connie I. Prosser Marianne E. Stewart Sander Veldhuyzen Zanten Daniel C. Sadowski | 2012 | International Journal of Colorectal Disease2012，，12： | 1 |
| 3 | Electrical Activity from Colon Overlaps with Normal Gastric Electrical Activity in Cutaneous Recordings显示文摘 | Manuel A. Amaris Claudia P. Sanmiguel Daniel C. Sadowski Kenneth L. Bowes Martin P. Mintchev | 2002 | Digestive Diseases and Sciences2002，，11： | 1 |
| 4 | Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation显示文摘AIM:To investigate genetic differences between Crohn's disease(CD) patients with a sustained remission vs relapsers after discontinuing infliximab while in corticosteroid-free remission.METHODS:Forty-eight CD patients received infliximab and were in full corticosteroid-free clinical remission but then discontinued infliximab for reasons other than a loss of response,were identified by review of an electronic database and charts.Infliximab-associated remission was defined as corticosteroid-free plus normalization of clinical disease activity [CD activity index(CDAI) < 150] during follow-up visits based on physician global assessments.A CD relapse(loss of infliximab-induced remission) was clinically defined as a physician visit for symptoms of disease activity(CDAI > 220) and a therapeutic intervention with CD medication(s),or a hospitalization with complications related to active CD.Genetic analyses were performed on samples from 14 patients(n = 6 who had a sustained long term remission after stopping infliximab,n = 8 who rapidly relapsed after stopping infliximab).Nucleotide-binding oligomerization domain 2(NOD2)/caspase activation recruitment domain 15(CARD15) polymorphisms(R702W,G908R and L1007fs) and the inflammatory bowel disease 5(IBD5) polymorphisms(IGR2060a1 and IGR3081a1) were analyzed in each group.RESULTS:Five single nucleotide polymorphisms of IBD5 and NOD2/CARD15 genes were successfully analyzed for all 14 subjects.There was no significant increase in frequency of the NOD2/CARD15 polymorphisms(R702W,G908R and L1007fs) and the IBD5 polymorphisms(IGR2060a1 and IGR3081a1) in either group of patients;those whose disease relapsed rapidly or those who remained in sustained long term remission following the discontinuation of infliximab.Nearly a third of patients in full clinical remission who stopped infliximab for reasons other than loss of response remained in sustained clinical remission,while two-thirds relapsed rapidly.There was a marked difference in the duration of clinical remission following discontinuance of infliximab between the two groups.The patients who lost remission did so after 1.0 years ± 0.6 years,while those still in remission were at the time of this study,8.1 years ± 2.6 years post-discontinuation of infliximab,P < 0.001.The 8 patients who had lost remission after discontinuing infliximab had a mean number of 5 infusions(range 3-7),with a mean treatment time of 7.2 mo(range 1.5 mo-15 mo).The mean duration of time from the last infusion of infliximab to the time of loss of remission was 382 d(range 20 d-701 d).The 6 patients who remained in remission after discontinuing infliximab had a mean number of 6 infusions(range 3-12),with a mean treatment duration of 12 mo(range 3.6 mo-32 mo)(P = 0.45 relative to those who lost remission).CONCLUSION:There are no IBD5 or NOD2/CARD15 mutations that predict which patients might have sustained remission and which will relapse rapidly after stopping infliximab. | Cathy Lu Alistair Waugh Robert J Bailey Raeleen Cherry Levinus A Dieleman Leah Gramlich Kata Matic Mario Millan Karen I Kroeker Daniel Sadowski Christopher W Teshima Dennis Todoruk Clarence Wong Karen Wong Richard N Fedorak | 2012 | World Journal of Gastroenterology2012，18，36： | 1 |
| 5 | Intestinal lamina propria dendritic cells maintain T cell homeostasis but do not affect commensalism显示文摘 | Nathan E. Welty Christopher Staley Nico Ghilardi Michael J. Sadowsky Botond Z. Igyártó Daniel H. Kaplan | 2013 | Journal of Experimental Medicine2013，，10： | 1 |
| 6 | Tensile and tear-type fracture toughness of gypsum material:Direct and indirect testing methods显示文摘In this context,four specimens,i.e.(i)circumferentially notched cylindrical torsion(CNCT),(ii)circum-ferentially notched cylindrical direct tension(CNCDT),(iii)edge notch disc bend(ENDB)and(iv)three-point bend beam(3PBB),were utilized to measure the modesⅠandⅢfracture toughness values of gypsum.While the CNCT specimen provides pure modeⅢloading in a direct manner,this pure mode condition is indirectly produced by the ENDB specimen.The ENDB specimen provided lower KⅢc and a non-coplanar(i.e.twisted)fracture surface compared with the CNCT specimen,which showed a planar modeⅢfracture surface.The ENDB specimen is also employed for conducting pure modeⅠ(with different crack depths)and mixed modeⅠ/Ⅲtests.KIc value was independent of the notch depth,and it was consistent with the RILEM and ASTM standard methods.But the modeⅢfracture results were highly sensitive to the notch depth.While the fracture resistance against modeⅢwas significantly lower than that of modeⅠ,the greater work of fracture under modeⅢwas noticeable. | Daniel Pietras M.R.M.Aliha Hadi G.Kucheki Tomasz Sadowski | 2023 | Journal of Rock Mechanics and Geotechnical Engineering2023，15，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员